ArticleFrontiers in immunology2025
Human pluripotent stem cell-derived neuronal progenitor cells promote neurogenesis and functional recovery by attenuating neuroinflammation and via extracellular vesicles in a subacute stroke model.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton's Jelly Mesenchymal Stem Cells in the Orchestrum.Brain sciences · 2026Review
- Neural Stem/Progenitor Cells Regulate Neuroinflammation: Mechanisms and Therapeutic Applications in Neurological Diseases.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stroke remains a leading cause of long-term disability worldwide. The limited therapeutic window of current treatments underscores the need for alternative regenerative strategies. Neural progenitor cells (NPCs) are promising candidates for brain repair. However, the optimal timing of therapy and the mechanisms underlying its effects on ischemic stroke remain unclear. Methods: To evaluate their efficacy, NPCs were administered intravenously to a subacute stroke (day 7) rat model. The outcomes were determined by comparison with saline treatment using neurobehavioral assessments, infarct volume measurements, and molecular assays. In addition, NPC secretome profiling was performed to assess the underlying cellular mechanisms. Results: The NPC group showed significant improvement in motor function at 3 weeks post-injection ( Discussion: NPC administration during the subacute phase of stroke promoted functional recovery by promoting neurogenesis and modulating key survival pathways. These results highlight the therapeutic potential of NPCs as cell-based interventions for delayed stroke treatment and provide mechanistic insights into their reparative effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.